title: Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
abstract: BACKGROUND
  There are no published randomised trials on the efficacy of enzalutamide against metastatic castrate-resistant prostate cancer (mCRPC) after docetaxel and abiraterone. We evaluated the activity of third-line enzalutamide in men with mCRPC after docetaxel and abiraterone.
  
  
  METHODS
  Progression-free (PFS) and overall (OS) survival from the start of enzalutamide were compared according to response to abiraterone in men with mCRPC treated at a single cancer centre.
  
  
  RESULTS
  Median PFS and OS for the whole 34-patient cohort from starting enzalutamide were 2.7 months (95% confidence interval=1.4-4.0 months) and 10.4 months (95% confidence interval=9.0-11.7 months). There was no significant difference in PFS and OS in patients according to prostate-specific antigen response to abiraterone (≥50% vs. <50%, ≤ or >6 months).
  
  
  CONCLUSIONS
  In mCRPC, enzalutamide has modest activity after docetaxel and abiraterone. Response to previous abiraterone is not predictive of subsequent enzalutamide response.
authors.affiliation: Velindre Cancer Centre, Cardiff, Wales, U.K. rhian.s.davies@wales.nhs.uk.
authors.forename: Rhian Siân
authors.initials: RS
authors.lastname: Davies
authors.affiliation: Velindre Cancer Centre, Cardiff, Wales, U.K.
authors.forename: Christian
authors.initials: C
authors.lastname: Smith
authors.affiliation: Velindre Cancer Centre, Cardiff, Wales, U.K.
authors.forename: Jason Francis
authors.initials: JF
authors.lastname: Lester
mesh_terms: D000368:Aged; D000736:Androstenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D000077143:Docetaxel; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D043823:Taxoids; D000077143:Docetaxel; D010669:Phenylthiohydantoin; C540278:enzalutamide; D017430:Prostate-Specific Antigen; C089740:abiraterone
keywords: Metastatic; castrate-resistant; drug sequencing; enzalutamide; prostate cancer; third line